Enzyme replacement therapy for mucopolysaccharidosis II from 3 months of age: A 3-year follow-up

Acta Paediatrica, International Journal of Paediatrics

Volumn 101, Issue 1, 2012, Pages

  Tylki Szymanska, A ^a   Jurecka, A ^a,b   Zuber, Z ^c   Rozdzynska, A ^a   Marucha, J ^a   Czartoryska, B ^d  

^a CHILDREN'S MEMORIAL HEALTH INSTITUTE   (Poland)

^b UNIVERSITY OF GDA SK   (Poland)

^c S Louis Regional Children's Hospital   (Poland)

^d INSTITUTE OF PSYCHIATRY AND NEUROLOGY   (Poland)

Author keywords

Enzyme replacement therapy; Hunter syndrome; Idursulfase; Mucopolysaccharidosis II

Indexed keywords

IDURONATE 2 SULFATASE;

ABDOMINAL RADIOGRAPHY; ANTHROPOMETRY; ARTICLE; AUDIOLOGY; BONE RADIOGRAPHY; CASE REPORT; CHILD; CLINICAL FEATURE; DISEASE COURSE; ECHOCARDIOGRAPHY; ENZYME REPLACEMENT; FEMALE; FOLLOW UP; HUMAN; HUNTER SYNDROME; INFANT; INTELLECTUAL IMPAIRMENT; LIVER; LONG TERM CARE; MALE; PATIENT COMPLIANCE; PRESCHOOL CHILD; PRIORITY JOURNAL; PSYCHOLOGIC TEST; RANGE OF MOTION; SCHOOL CHILD; SPLEEN; TREATMENT DURATION; TREATMENT OUTCOME; VERTEBRA MALFORMATION;

CHILD, PRESCHOOL; DISEASES IN TWINS; ENZYME REPLACEMENT THERAPY; FOLLOW-UP STUDIES; HUMANS; IDURONATE SULFATASE; INFANT; MALE; MUCOPOLYSACCHARIDOSIS II; TREATMENT OUTCOME;

EID: 82955163121     PISSN: 08035253     EISSN: 16512227     Source Type: Journal    
DOI: 10.1111/j.1651-2227.2011.02385.x     Document Type: Article

References (16)

1. Neufeld EF, Muenzer J,. The mucopolysaccharidoses. In:, Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The metabolic and molecular basis of inherited disease, 8th edn. New York: McGraw-Hill, 2001: 3421-52.
2. Martin R, Beck M, Eng C, Giugliani R, Harmatz P, Munoz V, et al., Recognition and diagnosis of mucopolysaccharidosis II (Hunter syndrome). Pediatrics 2008; 121: e377-86. (Pubitemid 351198459)
3. Morini SR, Steiner CE, Passos Gerson LB,. Mucopolysaccharidosis type II: skeletal-muscle system involvement. J Ped Orthop B 2010; 19: 313-7.
4. Muenzer J, Wraith JE, beck M, Giugliani R, Harmatz P, Eng CM, et al., A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome). Genet Med 2006; 8: 465-73.
5. Muenzer J, Gucsavas-Calikoglu M, McCandless S, Schuetz T, Kimura A,. A phase I/II clinical trial of enzyme replacement therapy in mucopolysaccharidosis II (Hunter syndrome). Mol Genet Metab 2007; 90: 329-37. (Pubitemid 46241902)
6. Muenzer J, Beck M, Giugliani R, Suzuki Y, Tylki-Szymanska A, Valayannopoulos V, et al., Idursulfase treatment of Hunter syndrome in children younger than 6 years: results from the Hunter Outcome Survey. Genet Med 2011; 13: 102-9.
7. Kloska A, Jakobkiewicz-Banecka J, Tylki-Szymanska A, Czartoryska B, Wegrzyn G,. Female Hunter syndrome caused by a single mutation and familial XCI skewing: implications for other X-linked disorders. Clin Genet doi:.
8. Palczewska L, NiedÅwiecka Z,. WskaÅniki rozwoju somatycznego dzieci i mÅodzieÅy warszawskiej. Med Wieku Rozw 2001; 5: 1-120.
9. Auclair D, Hopwood JJ, Brooks DA, Lemontt JF, Crawley AC., Replacement therapy of mucopolysaccharidosis type VI: advantages of early onset therapy. Mol Genet Metab 2003; 78: 163-74. (Pubitemid 36332018)
10. Jonsson JJ, Aronovich EL, Braun SE, Whitley CB,. Molecular diagnosis of mucopolysaccharidosis type II (Hunter syndrome) by automated sequencing and computer-assisted interpretation: toward mutation mapping of the iduronate-2-sulfatase gene. Am J Hum Genet 1995; 56: 597-607.
11. Schulze-Frenking G, Jones S, Roberts J, Beck M, Wraith J,. Effects of enzyme replacement therapy on growth in patients with mucopolysaccharidosis type II. J Inherit Metab Dis 2011; 34: 203-8.
12. Tylki-Szymanska A, Rozdzynska A, Jurecka A, Marucha J, Czartoryska B,. Anthropometric data of 14 patients with mucopolysaccharidosis type I: restrospective analysis and efficacy of human recombinant alpha-L-iduronidase (laronidase). Mol Genet Metab 2010; 99: 10-7.
13. Rozdzynska A, Tylki-Szymanska A, Jurecka A, Cieslik J,. Growth pattern and growth prediction of body height in children with mucopolysaccharidosis type II. Acta Paediatr 2011; 100: 456-60.
14. Alcade-Martin C, Muro-Tudelilla JM, Cancho-Candela R, Gutierrez-Solana LG, Pintos-Morell G, Martí-Herrero M, et al., First experience of enzyme replacement therapy with idursulfase in Spanish patients with Hurler syndrome under 5 years of age: case observations from the Hunter Outcome Survey (HOS). Eur J Med Genet 2010; 53: 371-7.
15. Gabrielli O, Clarke LA, Bruni S, Coppa GV,. Enzyme replacement therapy in a 5-month-old boy with attenuated presymptomatic MPS I: 5-year follow-up. Pediatrics 2010; 125: e183-7.
16. McGill JJ, Inwood AC, Coman DJ, Lipke ML, de Lore D, Swiedler SJ, et al., Enzyme replacement therapy for mucopolysaccharidosis VI from 8 weeks of age-a sibling control study. Clin Genet 2010; 77: 492-8.